P-030 Dramatic rise in uterine carcinosarcoma in the COVID years: A case series at a DGH

Published Date: 09th October 2024

Publication Authors: Sharples. S

Objective
Uterine carcinosarcoma (USC) is a rare gynaecological malignancy representing less than 5% of all uterine cancers. It is usually associated with a late presentation and poor prognosis. During the COVID pandemic years of 2020–2023, we saw a dramatic rise in the rate of USC at our DGH. The purpose of this case series was to explore this rise and determine if there were any trends that could be identified.

Methods
We reviewed each of the cases individually, looking at patient's background, past medical history and presentation.

Results
Rates of UCS within our DGH are usually 1 to 2 cases a year. In 2020 we had a rise to 5 cases and in 2021 we had 8 cases. In 2022 the rates dropped to 6 cases and then 5 cases in 2023. Interestingly our endometrial cancer rates have stayed static at around 50 a year, so this is not a proportional rise. Rates prior to 2020 of UCS have been stable. There is striking rise of UCS during the COVID pandemic that has not been seen before. No obvious trend was found between each of the patients reviewed, other than the time period of the pandemic.

Conclusion
The impact and the unusual effect COVID has had on patterns of disease is interesting. Identifying changes in trends is vital in the hope that as we gather more information on this virus, and we can have a better understanding as to why we have seen these changes.

Sharples; S. (2024). P-030 Dramatic rise in uterine carcinosarcoma in the COVID years: A case series at a DGH. BJOG: An International Journal of Obstetrics and Gynaecology. 131(S4), p.54. [Online]. Available at: https://dx.doi.org/10.1111/1471-0528.17941 [Accessed 24 December 2025]